On Monday, Canaccord Genuity sustained its positive stance on DexCom (NASDAQ:DXCM) shares, maintaining both a Buy rating and an $89.00 price target. The firm's analyst shared insights from a personal trial of continuous glucose monitoring (CGM) devices, including DexCom's Stelo and Abbott's Lingo, as well as Abbott's prescription-only Libre 3, which was tested by a colleague.
The analyst's experience highlighted the impact of nutrition and exercise on glucose levels, noting the similarity in consumer app features between the DexCom and Abbott devices. However, a notable distinction was made in terms of user accessibility; DexCom's app is available on both iOS and Android platforms, whereas Abbott's is currently iOS-only.
In terms of pricing and purchasing options, both companies offer similar daily pricing, but Abbott provides more flexibility with three purchase options compared to DexCom's two. The trial did not reveal a significant difference in the quantity or quality of data provided by the consumer devices.
The personal trial also prompted consideration of the potential for users to discover pre-diabetic conditions or type 2 diabetes (T2D) through the use of these consumer devices, which may lead to ongoing usage or consultation with a physician for prescription CGM devices.
The analyst plans to revisit the devices in six months, having only utilized one sensor from each company during the trial, despite purchasing two. The long-term impact on user behavior and health monitoring remains to be seen.
In other recent news, DexCom, a medical device company, has been the subject of several analyst adjustments following its second-quarter earnings report. The company reported a 15.3% increase in earnings, reaching $1,004 million, which fell short of the projected $1,049 million.
As a result, RBC Capital cut its price target for DexCom from $145.00 to $130.00, while maintaining an Outperform rating. In contrast, Piper Sandler maintained an Overweight rating on DexCom shares, expressing confidence in the company's future performance despite competition in the diabetes management sector.
In addition to its financial results, DexCom also announced a strategic partnership with Tandem Diabetes Care (NASDAQ:TNDM). The t:slim X2 insulin pump software now supports both DexCom G7 and G6 Continuous Glucose Monitoring (CGM) Systems. This marks a significant advancement in diabetes management technology.
In terms of market competition, Abbott recently launched its over-the-counter continuous glucose monitoring system, Lingo, which is aimed at adults who do not require insulin. This product release follows the launch of a similar device by DexCom.
Despite these developments, DexCom remains confident in its growth potential. The company revised its full-year revenue guidance to 11% to 13% organic growth, with revenue expectations between $4.00 billion and $4.05 billion. These recent developments underscore the dynamic landscape of the diabetes management market and the ongoing efforts by companies like DexCom to innovate and grow.
InvestingPro Insights
DexCom's financial metrics and market performance offer additional context to the analyst's positive outlook. According to InvestingPro data, DexCom has demonstrated strong revenue growth, with a 23.05% increase in the last twelve months as of Q2 2024, reaching $3.93 billion. This growth aligns with the company's expanding presence in the continuous glucose monitoring market.
Despite recent market volatility, with the stock price falling 40.09% over the last three months, DexCom maintains a solid financial position. An InvestingPro Tip highlights that the company's cash flows can sufficiently cover interest payments, indicating financial stability. This could be crucial as DexCom continues to innovate and compete in the CGM space.
Another relevant InvestingPro Tip notes that DexCom is trading at a low P/E ratio relative to near-term earnings growth, with a PEG ratio of 0.47. This suggests potential undervaluation, which may support Canaccord Genuity's Buy rating and price target.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips on DexCom, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.